BioLineRx PT Lowered to $7.00 (BLRX)
Analysts at Aegis lowered their price target on shares of BioLineRx (NASDAQ: BLRX) from $11.00 to $7.00 in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the stock.
BioLineRx (NASDAQ: BLRX) traded down 53.02% on Wednesday, hitting $1.7899. BioLineRx has a 52-week low of $2.20 and a 52-week high of $5.10. The stock’s 50-day moving average is currently $3.9. The company’s market cap is $39.5 million.
BioLineRX Ltd. is an Israel-based company engaged in identifying and following the critical pathway to commercialization of therapeutic compounds.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
Quaint notion, but the only thing i fear more than the Fed is whatever monstrocity replaces it. As for transparency, ...
All their employees getting laid off with no chance of getting called back in Middlebury Indiana sure don't see any ...
What is wrong with this picture. Everyone has a price of $14-15, but these clowns come out with $4-5. ...